Second primary malignancy in myelofibrosis patients treated with ruxolitinib-Reference-Cited by-同舟云学术

Second primary malignancy in myelofibrosis patients treated with ruxolitinib

Published:2020-11-21 Issue:2 Volume:193 Page:356-368
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br. J. Haematol.

Author:

Polverelli Nicola¹^ORCID,Elli Elena M.²,Abruzzese Elisabetta³^ORCID,Palumbo Giuseppe A.⁴,Benevolo Giulia⁵,Tiribelli Mario⁶^ORCID,Bonifacio Massimiliano⁷,Tieghi Alessia⁸,Caocci Giovanni⁹,D'Adda Mariella¹⁰,Bergamaschi Micaela¹¹,Binotto Gianni¹²^ORCID,Heidel Florian H.¹³,Cavazzini Francesco¹⁴,Crugnola Monica¹⁵,Pugliese Novella¹⁶^ORCID,Bosi Costanza¹⁷,Isidori Alessandro¹⁸,Bartoletti Daniela¹⁹^ORCID,Auteri Giuseppe¹⁹,Latagliata Roberto²⁰,Gandolfi Lisa¹,Martino Bruno²¹,Scaffidi Luigi⁷,Cattaneo Daniele²²,D’Amore Fabio¹²,Trawinska Malgorzata M.³,Stella Rossella⁶,Markovic Uros²³,Catani Lucia¹⁹^ORCID,Pane Fabrizio¹⁶,Cuneo Antonio¹⁴,Krampera Mauro⁷,Semenzato Gianpietro¹²,Lemoli Roberto M.¹¹,Vianelli Nicola¹⁹,Breccia Massimo²⁰^ORCID,Russo Domenico¹,Cavo Michele¹⁹,Iurlo Alessandra²²^ORCID,Palandri Francesca¹⁹

Affiliation:

1. Unit of Blood Diseases and Stem Cell Transplantation Department of Clinical and Experimental Sciences University of BresciaASST Spedali Civili of Brescia BresciaItaly

2. Haematology Division San Gerardo HospitalASST Monza MonzaItaly

3. Division of Haematology Ospedale S. Eugenio RomaItaly

4. Department of Scienze Mediche, Chirurgiche e Tecnologie Avanzate “G.F. Ingrassia” University of Catania CataniaItaly

5. Division of Haematology Città della Salute e della Scienza Hospital TorinoItaly

6. Division of Haematology and BMT Azienda Sanitaria Universitaria Integrata di Udine UdineItaly

7. Department of Medicine Section of Haematology University of Verona VeronaItaly

8. Department of Haematology Azienda USL ‐ IRCCS di Reggio Emilia Reggio EmiliaItaly

9. Department of Medical Sciences and Public Health Haematology UnitUniversity of Cagliari CagliariItaly

10. Division of Haematology ASST Spedali Civili of Brescia Brescia Italy

11. Department of Internal Medicine (DiMI) Clinic of Haematology IRCCS AOU San Martino‐IST GenovaItaly

12. Unit of Haematology and Clinical Immunology University of Padova Padova Italy

13. Internal Medicine IIHaematology and Oncology, Friedrich‐Schiller‐University Medical Center Jena Germany

14. Division of Haematology University of Ferrara FerraraItaly

15. Division of Haematology Azienda Ospedaliero‐Universitaria di Parma ParmaItaly

16. Department of Clinical Medicine and Surgery University of Naples Federico II NaplesItaly

17. Division of Haematology AUSL di Piacenza PiacenzaItaly

18. Haematology and Stem Cell Transplant Center Marche Nord Hospital PesaroItaly

19. Azienda Ospedaliero‐Universitaria di Bolognavia Albertoni 15 BolognaItaly

20. Division of Cellular Biotechnologies and Haematology University Sapienza RomaItaly

21. Division of Haematology Azienda Ospedaliera “Bianchi Melacrino Morelli” Reggio CalabriaItaly

22. Haematology Division Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico MilanItaly

23. Division of Haematology AOU Policlinico‐Vittorio Emanuele, University of Catania Catania Italy

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17192

Reference63 articles.

1. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

2. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment

3. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

4. Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options

5. Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors;American Journal of Clinical Dermatology;2024-01-12

2. Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib;Blood;2024-01-11

3. Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination;Frontiers in Oncology;2023-06-07

4. Cytokine nanosponges suppressing overactive macrophages and dampening systematic cytokine storm for the treatment of hemophagocytic lymphohistiocytosis;Bioactive Materials;2023-03

5. Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: Methotrexate, alkylating agents, biologics, and small molecule inhibitors;Journal of the American Academy of Dermatology;2023-03